Eccrine squamous syringometaplasia in sites of radiation recall secondary to vemurafenib therapy for BRAF-mutated carcinoma.
Section of Dermatology, University of Chicago, Chicago, Illinois, USA.
Eduardo K
EK
Moioli
Section of Dermatology, University of Chicago, Chicago, Illinois, USA.
Katherine G
KG
Ligtenberg
Section of Dermatology, University of Chicago, Chicago, Illinois, USA.
Sonya
S
Kenkare
Section of Dermatology, University of Chicago, Chicago, Illinois, USA.
Christopher R
CR
Shea
Section of Dermatology, University of Chicago, Chicago, Illinois, USA. ksoltani@medicine.bsd.uchicago.edu.
Keyoumars
K
Soltani
D000230:Adenocarcinoma / Q000235:genetics / Q000628:therapy; D000077192:Adenocarcinoma of Lung; D000279:Administration, Cutaneous; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D004439:Eccrine Glands / Q000473:pathology*; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004890:Erythema / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000235:genetics / Q000628:therapy; D008297:Male; D008679:Metaplasia / Q000209:etiology / Q000473:pathology; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology; D011855:Radiodermatitis / Q000139:chemically induced* / Q000473:pathology; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D013543:Sweat Gland Diseases / Q000209:etiology* / Q000473:pathology; D000077484:Vemurafenib
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf